Funding For All

John Ruffin thinks the National Institutes of Health's 20-year effort to ensure that affirmative action goals are carried out through minority research and training programs must have been a benefit to society. But he can't really say that for sure--because he just doesn't know. No one is keeping track. And in order to find out just how effective NIH is in moving and keeping minorities in research careers, Ruffin is heading a multiyear effort to evaluate the various programs aimed at minorities

Written byRenee Twombly
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

"There has never been a serious assessment of these programs, so all we have ever been able to do is speak anecdotally about their value," says Ruffin, associate director for research on minority health, in the Office of the NIH Director. "Once we figure out what we have got, and how effective it is, we may adjust, modify, or eliminate. The budget problem is real; we don't want to waste any money but we want solutions.

"The NIH spends far less than 1 percent of its budget for their minority programs, but I, for one, want to conduct a national study that speaks of results. I want to document success."

The oldest of the programs are some of its largest, and most expensive, costing, for example, $78 million in 1991. The Minority Access to Research Careers (MARC) and the Minority Biomedical Research Support (MBRS) started in 1972, while the Research ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies